Please ensure Javascript is enabled for purposes of website accessibility

Diving Into the Johnson & Johnson Earnings Report

By Brenton Flynn - Updated Apr 7, 2017 at 12:21PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Johnson & Johnson is bucking a recent trend in the health care arena. That trend has been the perceived "unlocking" of value through spinoffs and other transactions. In fact, two of the biggest players in health care -- Abbott Labs (ABT 0.20%) and Pfizer (PFE -3.32%) -- are making moves of their own in the near future.

Abbott is shedding its branded pharmaceuticals business into a stand-alone company called AbbVie, while Pfizer is planning to sell a 20% stake in its animal-health business through an IPO of a new stand-alone company called Zoetis. Many have looked to J&J to go the same route, but management remains committed to one of its strategic principles of maintaining a broad base in human health care.

In the following video, Fool.com health care bureau chief Brenton Flynn and health care analyst Max Macaluso discuss earnings from Johnson & Johnson, and how its balanced portfolio served the company in the latest quarter.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool owns shares of Intuitive Surgical and Johnson & Johnson. Motley Fool newsletter services recommend Intuitive Surgical, Johnson & Johnson, and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$48.29 (-3.32%) $-1.66
Abbott Laboratories Stock Quote
Abbott Laboratories
ABT
$110.49 (0.20%) $0.22
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$167.14 (-2.07%) $-3.53
Intuitive Surgical, Inc. Stock Quote
Intuitive Surgical, Inc.
ISRG
$236.02 (-0.77%) $-1.83
Vertex Pharmaceuticals Incorporated Stock Quote
Vertex Pharmaceuticals Incorporated
VRTX
$292.16 (-1.22%) $-3.61

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
390%
 
S&P 500 Returns
125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.